•Prenatal opioid exposure tied to poorer vision, attention in kids•Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization•Dexamethasone eye drops may cut invasive ROP treatment in preterm infants•Nacuity doses first patient in phase 3 trial on oral therapy for RP associated with Usher syndrome•Simple OCT rule helps cut glaucoma false positives in myopia•Prenatal opioid exposure tied to poorer vision, attention in kids•Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization•Dexamethasone eye drops may cut invasive ROP treatment in preterm infants•Nacuity doses first patient in phase 3 trial on oral therapy for RP associated with Usher syndrome•Simple OCT rule helps cut glaucoma false positives in myopia
HEADLINES
FEATURED
Federal agency issues new safety warning following new evidence; will now require all manufactures to update medication labels.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
